NDAOPHTHALMICSOLUTION/DROPS
Approved
Jul 2025
Lifecycle
Growth
Competitive Pressure
0/100
Clinical Trials
2
Data completeness
3/8 — Basic
Drug data last refreshed 21h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
VIZZ (aceclidine) is an ophthalmic solution approved by the FDA on July 31, 2025, for use as eye drops. The mechanism of action and specific indication are not disclosed in available data. This product is a small-molecule therapeutic delivered via topical ocular administration.
Growth17.5 years to LOE
Early-stage commercial asset with growth potential; expect expanding field teams and marketing infrastructure as label uptake accelerates post-launch.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (2)
Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia
Started Aug 2022
59 enrolled
PresbyopiaRefractive ErrorsEye Diseases
Evaluation of the Safety and Effectiveness of Aceclidine/Brimonidine (LNZ101) and Aceclidine (LNZ100) in the Treatment of Presbyopia
Started May 2022
68 enrolled
PresbyopiaRefractive ErrorsEye Diseases
Career Relevance
VIZZ represents a growth-stage ophthalmic specialty product with minimal competitive clutter and a 17.5-year patent runway, creating stable career opportunities in brand management, field sales, and medical affairs. Early-mover status provides visibility and influence in a nascent market segment, ideal for professionals seeking to build a franchise from launch.
Worked on VIZZ at LENZ Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.